Citation: K. Fiedler et al., Detection of microbial volatile organic compounds (MVOCs) produced by moulds on various materials, INT J HYG E, 204(2-3), 2001, pp. 111-121
Authors:
Schmidt, H
Tlustochowska, A
Stuertz, K
Djukic, M
Gerber, J
Schutz, E
Kuhnt, U
Nau, R
Citation: H. Schmidt et al., Organotypic hippocampal cultures - A model of brain tissue damage in Streptococcus pneumoniae meningitis, J NEUROIMM, 113(1), 2001, pp. 30-39
Authors:
Gerber, J
Smirnov, A
Wellmer, A
Ragheb, J
Prange, J
Schutz, E
Wettich, K
Kalich, S
Nau, R
Citation: J. Gerber et al., Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin, ANTIM AG CH, 45(7), 2001, pp. 2169-2172
Authors:
Braun, F
Schutz, E
Peters, B
Talaulicar, R
Grupp, C
Undre, N
Schafer, A
Armstrong, VW
Oellerich, M
Ringe, B
Citation: F. Braun et al., Pharmacokinetics of tacrolimus primary immunosuppression in kidney transplant recipients, TRANSPLAN P, 33(3), 2001, pp. 2127-2128
Authors:
Shipkova, M
Wieland, E
Schutz, E
Wiese, C
Niedmann, PD
Oellerich, M
Armstrong, VW
Citation: M. Shipkova et al., The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes, TRANSPLAN P, 33(1-2), 2001, pp. 1080-1081
Authors:
Ringe, B
Braun, F
Schutz, E
Fuzesi, L
Lorf, T
Canelo, R
Oellerich, M
Ramadori, G
Citation: B. Ringe et al., A novel management strategy of steroid-free immunosuppression after liver transplantation: Efficacy and safety of tacrolimus and mycophenolate mofetil, TRANSPLANT, 71(4), 2001, pp. 508-515
Authors:
Kruis, W
Schreiber, S
Theuer, D
Brandes, JW
Schutz, E
Howaldt, S
Krakamp, B
Hamling, J
Monnikes, H
Koop, I
Stolte, M
Pallant, D
Ewald, U
Citation: W. Kruis et al., Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three timesdaily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses, GUT, 49(6), 2001, pp. 783-789
Authors:
Shipkova, M
Armstrong, VW
Kiehl, MG
Niedmann, PD
Schutz, E
Oellerich, M
Wieland, E
Citation: M. Shipkova et al., Quantification of mycophenolic acid in plasma samples collected during andimmediately after intravenous administration of mycophenolate mofetil, CLIN CHEM, 47(8), 2001, pp. 1485-1488
Citation: N. Von Ahsen et al., Oligonucleotide melting temperatures under PCR conditions: Nearest-neighbor corrections for Mg2+, deoxynucleotide triphosphate, and dimethyl sulfoxide concentrations with comparison to alternative empirical formulas, CLIN CHEM, 47(11), 2001, pp. 1956-1961
Authors:
Wieland, E
Shipkova, M
Schutz, E
Braun, F
Niedmann, PD
Armstrong, VW
Ringe, B
Svinarov, DA
Oellerich, M
Citation: E. Wieland et al., Preliminary report on the effect of xenoperfusion with human blood on cyclosporin A metabolism and cytochrome-P-4503A4-mRNA expression in a pig liverperfusion model, CLIN BIOCH, 34(1), 2001, pp. 53-57
Authors:
Pickenpack, A
Straub, RH
Distler, O
Hammond, A
Oellerich, M
Scholmerich, J
Lang, B
Schutz, E
Citation: A. Pickenpack et al., Safety and efficacy of an intravenous loading dose of azathioprine for treatment of non-TPMT-deficient patients with rheumatic diseases, RHEUMATOLOG, 39(12), 2000, pp. 1435-1436
Authors:
Bardhan, KD
Bodemar, G
Geldof, H
Schutz, E
Heath, A
Mills, JG
Jacques, LA
Citation: Kd. Bardhan et al., A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome, ALIM PHARM, 14(1), 2000, pp. 23-34
Authors:
Oellerich, M
Shipkova, M
Schutz, E
Wieland, E
Weber, L
Tonshoff, B
Armstrong, VW
Citation: M. Oellerich et al., Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: Implications for therapeutic drug monitoring (vol 1, pg 20, 2000), THER DRUG M, 22(4), 2000, pp. 500-500
Authors:
Oellerich, M
Shipkova, M
Schutz, E
Wieland, E
Weber, L
Tonshoff, B
Armstrong, VW
Citation: M. Oellerich et al., Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: Implications for therapeutic drug monitoring, THER DRUG M, 22(1), 2000, pp. 20-26
Authors:
von Ahsen, N
Lewczuk, P
Schutz, E
Oellerich, M
Ehrenreich, H
Citation: N. Von Ahsen et al., Prothrombin activity and concentration in healthy subjects with and without the prothrombin G20210A mutation, THROMB RES, 99(6), 2000, pp. 549-556
Authors:
Braun, F
Lorf, T
Schutz, E
Canelo, R
Hanack, U
Dopkens, K
Sattler, B
Grupp, C
Ringe, B
Citation: F. Braun et al., Primary tacrolimus immunosuppression in kidney recipients considered "higher immunological risk", TRANSPLAN P, 32(7), 2000, pp. 1688-1688
Authors:
Braun, F
Christians, U
Laabs, S
Elias, K
Shipkova, M
Schutz, E
Ringe, B
Citation: F. Braun et al., An ex vivo model to study the intestinal biotransformation of immunosuppressive drugs, TRANSPLAN P, 32(7), 2000, pp. 1999-1999
Authors:
Braun, F
Lorf, T
Schutz, E
Canelo, R
Hanack, U
Dopkens, K
Sattler, B
Grupp, C
Ringe, B
Citation: F. Braun et al., Primary tacrolimus immunosuppression in kidney recipients considered "higher immunologic risk", TRANSPLAN P, 32(7), 2000, pp. 2535-2535